JPWO2020159368A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020159368A5 JPWO2020159368A5 JP2021544622A JP2021544622A JPWO2020159368A5 JP WO2020159368 A5 JPWO2020159368 A5 JP WO2020159368A5 JP 2021544622 A JP2021544622 A JP 2021544622A JP 2021544622 A JP2021544622 A JP 2021544622A JP WO2020159368 A5 JPWO2020159368 A5 JP WO2020159368A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- sequence shown
- antibody
- human
- multispecific antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024218893A JP2025032324A (ja) | 2019-02-01 | 2024-12-13 | 新規ｃｄ４０結合抗体 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL2022494 | 2019-02-01 | ||
| NL2022494A NL2022494B1 (en) | 2019-02-01 | 2019-02-01 | Novel CD40-binding antibodies |
| NL2024087 | 2019-10-23 | ||
| NL2024087 | 2019-10-23 | ||
| PCT/NL2020/050051 WO2020159368A1 (en) | 2019-02-01 | 2020-01-30 | Novel cd40-binding antibodies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024218893A Division JP2025032324A (ja) | 2019-02-01 | 2024-12-13 | 新規ｃｄ４０結合抗体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022519082A JP2022519082A (ja) | 2022-03-18 |
| JPWO2020159368A5 true JPWO2020159368A5 (enExample) | 2022-12-27 |
Family
ID=71840475
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021544622A Pending JP2022519082A (ja) | 2019-02-01 | 2020-01-30 | 新規ｃｄ４０結合抗体 |
| JP2024218893A Ceased JP2025032324A (ja) | 2019-02-01 | 2024-12-13 | 新規ｃｄ４０結合抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024218893A Ceased JP2025032324A (ja) | 2019-02-01 | 2024-12-13 | 新規ｃｄ４０結合抗体 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220135694A1 (enExample) |
| EP (1) | EP3917960A1 (enExample) |
| JP (2) | JP2022519082A (enExample) |
| KR (1) | KR20210141466A (enExample) |
| CN (1) | CN113993893A (enExample) |
| AU (1) | AU2020216250A1 (enExample) |
| BR (1) | BR112021015238A8 (enExample) |
| CA (1) | CA3128148A1 (enExample) |
| MX (1) | MX2021009285A (enExample) |
| SG (1) | SG11202108141VA (enExample) |
| WO (1) | WO2020159368A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023532807A (ja) | 2020-07-08 | 2023-07-31 | ラヴァ・セラピューティクス・エヌ・ヴイ | Ｐｓｍａ及びガンマ－デルタｔ細胞受容体に結合する抗体 |
| IL300517A (en) * | 2020-08-14 | 2023-04-01 | Gammadelta Therapeutics Ltd | Multispecific antibodies against variable chain delta 1 on TCR |
| EP4259660A1 (en) * | 2020-12-10 | 2023-10-18 | LAVA Therapeutics N.V. | Antibodies that bind gamma-delta t cell receptors |
| JP2024506682A (ja) * | 2021-02-17 | 2024-02-14 | ガンマデルタ セラピューティクス リミテッド | 抗ＴＣＲδ鎖可変部１抗体 |
| JP2024509332A (ja) | 2021-02-17 | 2024-02-29 | ガンマデルタ セラピューティクス リミテッド | 多重特異性抗ＴＣＲδ可変部１抗体 |
| AU2022292159A1 (en) | 2021-06-18 | 2023-12-21 | Autolus Limited | Anti-cd307e single-domain antibodies, uses thereof in car t-cell and for the treatment of diseases |
| WO2023025194A1 (zh) * | 2021-08-24 | 2023-03-02 | 江苏恒瑞医药股份有限公司 | Fap/cd40结合分子及其医药用途 |
| WO2023067138A1 (en) | 2021-10-21 | 2023-04-27 | LAVA Therapeutics N.V. | Uses of gamma delta t cell activating antibodies |
| CN119213028A (zh) * | 2022-01-05 | 2024-12-27 | 印希比生物科学有限公司 | 结合γδ T细胞的多肽及其用途 |
| CA3208653A1 (en) * | 2022-02-17 | 2022-08-25 | Mihriban Tuna | Multispecific anti-tcr delta variable 1 antibodies |
| EP4292609A1 (en) * | 2022-06-15 | 2023-12-20 | LAVA Therapeutics N.V. | Compositions comprising antibodies that bind gamma-delta t cell receptors |
| EP4292610A1 (en) | 2022-06-15 | 2023-12-20 | LAVA Therapeutics N.V. | Variant antibodies that bind gamma-delta t cell receptors |
| JP2025521865A (ja) * | 2022-06-28 | 2025-07-10 | ベイジン スターマブ バイオメド テクノロジ リミテッド | 単特異性抗体および多重特異性抗体 |
| CN116023495B (zh) * | 2022-09-05 | 2023-10-03 | 上海百英生物科技股份有限公司 | 一种抗cd40纳米抗体及其制备方法与应用 |
| WO2024092150A2 (en) * | 2022-10-26 | 2024-05-02 | Providence Health & Services - Oregon | Combination therapies utilizing microbially-expanded gamma delta t cells and t cell engaging biologics |
| US20250277048A1 (en) | 2024-03-01 | 2025-09-04 | Regeneron Pharmaceuticals, Inc. | The use of cd40 inhibitors for inhibiting an immune response and enabling immunogen administration and re-administration |
| WO2025184567A1 (en) | 2024-03-01 | 2025-09-04 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60143535D1 (de) * | 2000-10-02 | 2011-01-05 | Novartis Vaccines & Diagnostic | Humane antikörper gegen cd40 |
| US20100081792A1 (en) | 2001-06-28 | 2010-04-01 | Smithkline Beecham Corporation | Ligand |
| US10155816B2 (en) | 2005-11-28 | 2018-12-18 | Genmab A/S | Recombinant monovalent antibodies and methods for production thereof |
| US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
| US8927694B2 (en) | 2008-11-18 | 2015-01-06 | Merrimack Pharmaceuticals, Inc. | Human serum albumin linkers and conjugates thereof |
| JP2012521768A (ja) | 2009-03-27 | 2012-09-20 | ジモジェネティクス・インコーポレイテッド | 抗体−受容体の組み合わせを含む多特異的結合性タンパク質を用いるための組成物および方法 |
| KR101224468B1 (ko) | 2009-05-20 | 2013-01-23 | 주식회사 파멥신 | 신규한 형태의 이중표적항체 및 그 용도 |
| JP5997154B2 (ja) | 2010-08-16 | 2016-09-28 | ノビミューン エスアー | 多重特異性多価抗体の生成方法 |
| PL2699601T3 (pl) * | 2011-04-21 | 2018-05-30 | Bristol-Myers Squibb Company | Polipeptydy przeciwciała, które antagonizują CD40 |
| CN120383672A (zh) | 2012-04-20 | 2025-07-29 | 美勒斯公司 | 用于产生免疫球蛋白样分子的方法和手段 |
| WO2014081202A1 (ko) | 2012-11-21 | 2014-05-30 | 주식회사 파멥신 | Vegfr-2와 dll4를 표적으로 하는 이중표적항체 및 이를 포함하는 약학적 조성물 |
| EA039086B1 (ru) | 2014-04-10 | 2021-12-01 | Лава Терапьютикс Н.В. | Иммуноглобулины, связывающие человеческие v9v2 т-клеточные рецепторы |
| BR112019000512A2 (pt) * | 2016-07-14 | 2019-04-24 | Genmab A/S | anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, composição, métodos de tratamento de uma doença, para produzir um anticorpo biespecífico e para detectar se a reticulação entre as células que expressam cd40 e cd137 ocorre em uma amostra, uso de um anticorpo multiespecífico, e, kit |
| US11220550B2 (en) * | 2017-05-25 | 2022-01-11 | Bristol-Myers Squibb Company | Antagonistic anti-CD40 antibodies and methods of antagonizing CD40 activity |
-
2020
- 2020-01-30 JP JP2021544622A patent/JP2022519082A/ja active Pending
- 2020-01-30 EP EP20703313.5A patent/EP3917960A1/en active Pending
- 2020-01-30 CN CN202080018185.2A patent/CN113993893A/zh active Pending
- 2020-01-30 MX MX2021009285A patent/MX2021009285A/es unknown
- 2020-01-30 AU AU2020216250A patent/AU2020216250A1/en active Pending
- 2020-01-30 WO PCT/NL2020/050051 patent/WO2020159368A1/en not_active Ceased
- 2020-01-30 CA CA3128148A patent/CA3128148A1/en active Pending
- 2020-01-30 US US17/427,291 patent/US20220135694A1/en not_active Abandoned
- 2020-01-30 BR BR112021015238A patent/BR112021015238A8/pt unknown
- 2020-01-30 SG SG11202108141VA patent/SG11202108141VA/en unknown
- 2020-01-30 KR KR1020217027592A patent/KR20210141466A/ko active Pending
-
2024
- 2024-12-13 JP JP2024218893A patent/JP2025032324A/ja not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2020159368A5 (enExample) | ||
| JP2020501531A5 (enExample) | ||
| CN105968206B (zh) | 抗erbb3抗体 | |
| EP3645742A2 (en) | Anti-ror1 antibodies and methods of making and using thereof | |
| JP2018503380A5 (enExample) | ||
| CN115052893A (zh) | 抗tigit抗体和使用方法 | |
| RU2013125457A (ru) | Комбинация антител против с-мет | |
| JP2020504723A5 (enExample) | ||
| JP2013545738A5 (enExample) | ||
| RU2009107494A (ru) | АНТИТЕЛА К ErbB2 | |
| RU2018114523A (ru) | Анти-tigit антитела и способы применения | |
| JPWO2019129221A5 (enExample) | ||
| JP2018519263A5 (enExample) | ||
| HRP20240149T1 (hr) | Bispecifična molekula za vezanje antigena, koji vežu cd3 i cd20, i njihove upotrebe | |
| JP2013527762A5 (enExample) | ||
| JP2014503205A5 (enExample) | ||
| CN112513094A (zh) | 结合人her2的抗体、其制备方法和用途 | |
| JP2020516309A5 (enExample) | ||
| RU2014153440A (ru) | Антитела против cd26 и их применение | |
| US20240101675A1 (en) | Dual binding antibodies, methods of producing dual binding antibodies, and uses thereof | |
| JP7731979B2 (ja) | 特異性が増強した二重特異性抗体（ｓｅｂａ） | |
| AU2020390028B2 (en) | Pharmaceutical composition, preparation method therefor and use thereof | |
| JPWO2020237173A5 (enExample) | ||
| JP2018529672A5 (enExample) | ||
| Amiri et al. | Hersintuzumab: A novel humanized anti-HER2 monoclonal antibody induces potent tumor growth inhibition |